Why Eton Pharmaceuticals, Inc.’s (ETON) Stock Is Down 5.98%
As of Friday, August 28, Eton Pharmaceuticals, Inc.’s ETON share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Commentary & Analysis
Why Eton Pharmaceuticals, Inc.’s (ETON) Stock Is Up 35.05%
As of Friday, August 14, Eton Pharmaceuticals, Inc.’s ETON share price has surged by 35.05%, which has investors questioning if this is right time to sell.Michael Rose
Why Eton Pharmaceuticals, Inc.’s (ETON) Stock Is Up 40.78%
As of Friday, August 14, Eton Pharmaceuticals, Inc.’s ETON share price has surged by 40.78%, which has investors questioning if this is right time to sell.Omar Beirat
What You Need to Know About Eton Pharmaceuticals, Inc.'s Q3 Earnings
Eton Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (ETON) missed or beat analyst's expectations.Michael Rose
Is Eton Pharmaceuticals, Inc. (ETON) Overvalued?
We dive into why Eton Pharmaceuticals, Inc. (ETON) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Financial Summary
| Share Statistics | ETON | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,691.5 | $550.7 | 52% |
|
| Shares Out (Mil) | 32.8 | 42.5 | 38% |
|
| Institutional Ownership | 91.6% | 84.5% | 60% |
|
| Float (Mil) | 22.3 | 45.7 | 31% |
|
| Beta | 0.87 | 0.73 | 52% |
|
| Avg Daily Volume (000s) | 497 | 448 | 55% |
|
| Price Change (52-week) |
193.8% | 61.4% | 98% |
|
| Growth | ETON | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | 30.3% | (1.4%) | 85% |
|
| EPS (5yr) | 33.7% | 15.1% | 84 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (1.4%) | (15.0%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | $0.370 | $1.400 | $2.580 | |
| Month Ago EPS | $0.370 | $1.400 | $2.580 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | $0.310 | $1.010 | $1.880 | |
| Year/Year Chg | 5.7% | (918.7%) | (2,036%) | |
| Financials | ETON | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $106 | $317 | 27% |
|
| Net Income (TTM) (Mil) | $13 | ($11) | 47% |
|
| EPS (TTM) | $0.467 | ($0.700) | 53% |
|
| Operating Cash Flow (TTM) (Mil) | $15 | ($7) | 40% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $5 | 47% |
|
| Long-Term Debt (Q1) (Mil) | $20 | $6 | 33% |
|
| Enterprise Value (Q1) (Mil) | $1,685 | $493 | 47% |
|
| Valuation | ETON | Industry Median |
Percentile (All Stocks) |
|
| P/B | 35.87 | 2.40 | 98% |
|
| P/E | 138.3 | 17.3 | 96% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 4.1 | 1.1 | 86% |
|
| Ratios | ETON | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.4% | 69.4% | 74% |
|
| Net Margin | 12.0% | 2.0% | 67% |
|
| ROA | 11.7% | (22.2%) | 90% |
|
| ROE | 36.0% | (22.8%) | 90% |
|
| Liabilities to Assets | 59.8% | 32.5% | 54% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 9/28/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.4% |
| +/- S&P 500: | +6.9 |
